Efficacy and Safety of BIIB111 for the Treatment of Choroideremia

PHASE3CompletedINTERVENTIONAL
Enrollment

169

Participants

Timeline

Start Date

December 11, 2017

Primary Completion Date

December 1, 2020

Study Completion Date

December 1, 2020

Conditions
Choroideremia
Interventions
GENETIC

BIIB111

Administered as specified in the treatment arm.

Trial Locations (18)

10032

Research Site, New York

21287

Research Site, Baltimore

33136

Research Site, Miami

45242

Research Site, Cincinnati

53127

Research Site, Bonn

53705

Research Site, Madison

75231

Research Site, Dallas

90095

Research Site, Los Angeles

97232

Research Site, Portland

H3A 0E7

Research Site, Montreal

V5Z 3N9

Research Site, Vancouver

Unknown

Research Site, Glostrup Municipality

Research Site, Montpellier

Research Site, Tübingen

Research Site, Nijmegen

00290

Research Site, Helsinki

M13 9WL

Research Site, Manchester

OX3 9DU

Research Site, Oxford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY